PDL1 detection set

PDL1 ELISA Matched Antibody Pair (Risk Free)

Cat. Num. AAA154806

• Reactivity: Human
• Applications: ELISA
• Purity: Mouse Monoclonal: Antibodies supplied as protein A purified IgG1.; ; Single Domain: Antibodies supplied as affinity chromatography purified via nickel column.
• Synonyms: PDL1; Monoclonal Detection Set; PDL1 ELISA Matched Antibody Pair (Risk Free); PDL1 detection set

• Host: Multiple
• Reactivity: Human
• Clonality: Monoclonal
• Isotype: IgG1 and sdab
• Purity/Purification: Mouse Monoclonal: Antibodies supplied as protein A purified IgG1.; ; Single Domain: Antibodies supplied as affinity chromatography purified via nickel column.
• Form/Format: Liquid. PBS containing 0.02% sodium azide.
• Concentration: Antibody 1mg/mL (varies by lot)

• Applicable Applications for PDL1 detection set: ELISA (EIA)
• Immunogen: PD-L1 antibodies were raised against the extracellular domain of human PD-L1.
• Conjugation: Unconjugated
• Preparation and Storage: Mouse Monoclonal: Antibodies can be stored at 4 degree C for three months and -20 degree C, stable for up to one year.; ; Single Domain: Antibody should be stored in working aliquots at -20 degree C, stable for up to one year.; ; As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Related Product Information for PDL1 detection set

Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antigen-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PD-L1 and PD-L2. PD-L1 is a B7-related protein that inhibits cell-mediated immune responses by reducing the secretion of IL-2 and IL-10 from memory T cells. This suggests that PD-L1 may be useful in reducing allogenic CD4+ memory T-cell responses to endothelial cells, thereby reducing the likelihood of host immune responses to allografts. Risk-FreeTM antibodies are mouse monoclonal antibodies made to improve in vivo studies. Unlike antibodies developed using proteins made in yeast or bacteria, Risk-FreeTM antibodies are developed with antigens expressed in mammalian cell lines, giving the most native post-translational modifications to the protein. Validated for flow cytometry and ELISA Rigorously tested for the following applications: Immunoblot Immunohistochemistry Immunocytochemistry Immunofluorescence. Multiple antibodies per target allowing the user to choose the best antibody for their application. Available individually or as a set Risk-FreeTM means they are guaranteed to work for their approved applications.

References

Holling TM, Schooten E, and van Den Elsing PJ. Function and regulation of MHC class II molecules in T-lymphocytes: of mice and men. Hum. Immunol. 2004; 65:282-90.
Ishida Y, Agata Y, Shibahara K, et al. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992; 11:3887-95.
LaGier J and Pober JS. Immune accessory functions of human endothelial cells are modulated by overexpression of B7-H1 (PDL1). Hum. Immunol. 2006; 67:568-78.
Aydin AM, Woldu SL, Hutchinson RC, et al. Spotlight on atezolizumab and its potential in the treatment of advanced urothelial bladder cancer.Onco. Targets Ther. 2017;10:1487-502.